A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
Inclusion Criteria:
Inclusion Criteria for the Extension Treatment Period
Exclusion Criteria:
History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study
Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD
Use of corticosteroids for the treatment of EoE within 8 weeks prior to Screening EGD
Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:
Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation
Used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to Baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time)
Use of any investigational agent or device within 12 weeks prior to Baseline
Females who are pregnant
Lancaster, California 93534, United States
Lancaster, California 93534, United States
Lancaster, California 93534, United States
Idaho Falls, Idaho 83404, United States
Gurnee, Illinois 60031, United States
Brick, New Jersey 08724, United States
Chapel Hill, North Carolina 27514, United States
Chapel Hill, North Carolina 27514, United States
Chapel Hill, North Carolina 27517, United States
Chapel Hill, North Carolina 27599-7064, United States
Cincinnati, Ohio 45219, United States
Wyomissing, Pennsylvania 19610, United States
Wyomissing, Pennsylvania 19610, United States
Wyomissing, Pennsylvania 19610, United States
Nashville, Tennessee 37212-1610, United States
Nashville, Tennessee 37232, United States
New Braunfels, Texas 78130, United States
San Marcos, Texas 78666, United States
Chesapeake, Virginia 23320, United States
Virginia Beach, Virginia 23464, United States
Brisbane South, Queensland 4101, Australia
Bellfield, 3081, Australia